A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Pletaal(Cilostazol) in Subjects With Vasospastic Angina
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Cilostazol (Primary)
- Indications Angina pectoris
- Focus Registrational; Therapeutic Use
- Acronyms STELLA
- Sponsors Korea Otsuka Pharmaceutical
- 01 May 2017 Status changed from recruiting to completed.
- 19 Oct 2014 Planned End Date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 19 Oct 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.